Literature DB >> 31678437

Rare NF1 Gene Mutation in Chinese Patient with Neurofibromatosis Type 1 and Anaplastic Astrocytoma.

Shizhen Zhou1, Yufang Zhu1, Jun Xu1, Rongjie Tao1, Shuanghu Yuan2.   

Abstract

BACKGROUND: Neurofibromatosis type 1 (NF1), a dysregulated neurocutaneous disorder, is an autosomal dominant genetic disease caused by mutations in the NF1 gene. Anaplastic astrocytoma is rare in NF1 patients, and research has proposed that high-grade astrocytomas could be due to larger germ-line mutations in NF1.We present a clinical and molecular study of a Chinese family with NF1. CASE DESCRIPTION: A 28-year-old male patient with NF1 presents with headache, vertigo, and dizziness. Histopathologic examination and molecular features identified a cerebellar anaplastic astrocytoma, IDH-wildtype. The patient underwent gross total resection of the lesion and received radiotherapy and chemotherapy. A rare splice error mutation (c.4110+945A>G) in intron 23-2 of NF1 was identified by next-generation sequencing in the proband. Sanger sequencing identified and confirmed it in some affected family members.
CONCLUSIONS: We present a unique case of NF1 with anaplastic astrocytoma that revealed a rare splice error mutation in the NF1 gene in the family. Published by Elsevier Inc.

Entities:  

Keywords:  Anaplastic astrocytoma; Gene mutation; Neurofibromatosis type 1

Mesh:

Substances:

Year:  2019        PMID: 31678437     DOI: 10.1016/j.wneu.2019.10.126

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  2 in total

1.  The gene diagnosis of neurofibromatosis type I with headache as the main symptom: A case report and review of the literature.

Authors:  Ming Gao; Haokun Liu; Qiying Sun; Guang Yang
Journal:  Front Neurol       Date:  2022-08-01       Impact factor: 4.086

Review 2.  The Anticancer Potential of Maslinic Acid and Its Derivatives: A Review.

Authors:  Lei Yu; Xiaofang Xie; Xiaoyu Cao; Junren Chen; Guanru Chen; Yan Chen; Gangmin Li; Junyuan Qin; Fu Peng; Cheng Peng
Journal:  Drug Des Devel Ther       Date:  2021-09-09       Impact factor: 4.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.